Significant synergy potential to providers and sponsors can be developed within the scope of a qualified and authorized subject-related provision of data. Here, the expertise of MEDSTAT S.A. can provide a significant contribution to the scaling of treatment outcomes in the context of chosen studies with regard to drugs and medical devices. These are thereby able to present better quality of medical outcomes beyond the initial admission and market introduction studies in the results.
The service offer of MEDSTAT S.A. for partners from the area of pharmaceutical industries and producers of medical devices includes:
- Risk-adjusted register studies
- Risk-adjusted prospective evaluations for different outcomes
- Health-economic studies in the area of pharmacy and medical devices industry
With our unique risk-adjusted tool we are able to support you in the conception and implementation of a broad spectrum of health-economic studies.
The introduction of new innovative products is always associated with significant irsks with regard to costs. For this reason you should chose us for support in the introduction of your new products.